sifalimumab

Home
Ligands
sifalimumab

GtoPdb Ligand ID: 8257

Synonyms: MDX-1103 | MEDI-545 | MEDI545

Comment: Sifalimumab is a monoclonal antibody targeting interferon α1 (IFNA1), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE). Development of sifalimumab was terminated and MedImmune concentrated on their alternative anti-IFNα agent anifrolumab.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Sequence BLAST using the heavy and light chain variable regions of sifalimumab provides 100% matches to sequences patented with application US7741449 [12]. The sequence matches identify sifalimumab as clone 13H5 in the patent.

No information available.

No information available.

Summary of Clinical Use
Sifalimumab reached Phase 2 clinical trial in patients with SLE. Results from NCT01283139 were promising, and although no efficacy of safety failures were reported [6], development of sifalimumab was discontinued for strategic business reasons in 2015.

Summary of Clinical Use

Sifalimumab reached Phase 2 clinical trial in patients with SLE. Results from NCT01283139 were promising, and although no efficacy of safety failures were reported [6], development of sifalimumab was discontinued for strategic business reasons in 2015.

Mechanism Of Action and Pharmacodynamic Effects
IFNα appears to enhance the maturation or activation of dendritic cells (DCs) [7-11], and increased expression of type I interferons has been described in several autoimmune diseases including SLE [1-2,5,13] and insulin-dependent diabetes mellitus (IDDM) [3]. The evidence validates IFNα as a drug target for the development of novel therapeutics for these diseases. Sifalimumab acts to neutralise circulating IFNα.

Mechanism Of Action and Pharmacodynamic Effects

IFNα appears to enhance the maturation or activation of dendritic cells (DCs) [7-11], and increased expression of type I interferons has been described in several autoimmune diseases including SLE [1-2,5,13] and insulin-dependent diabetes mellitus (IDDM) [3]. The evidence validates IFNα as a drug target for the development of novel therapeutics for these diseases. Sifalimumab acts to neutralise circulating IFNα.